Approval of the TactiFlex Duo was based on the results from Abbott's FlexPulse IDE study. Late-breaking data from the study ...

Abbott Laboratories has agreed to pay $670 million to settle a high-profile lawsuit and claims made on behalf of thousands of others related to allegations that its formula for babies born prematurely ...

These two high-quality dividend payers have had very different fortunes recently.

Abbott Laboratories said it received FDA approval for its TactiFlex Duo Ablation catheter as a treatment for people with abnormal heart rhythms. The healthcare company said Tuesday that the U.S.

Abbott Laboratories (ABT) delivered a strong Q2 2026 performance that surprised Wall Street, with the healthcare giant posting a double beat on both top and bottom lines on July 16, 2026. The earnings ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.

Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500’s 6% rise. This strong performance is due to the ...

Financial information summarized by Zonebourse indicates that Abbott Laboratories most recently reported group net income of ...

Abbott Laboratories will begin selling a new ready-to-feed version of its Similac infant formula Monday, marking the first ...